AbbVie Inc. (ABBV) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, AbbVie reported revenue of $61.16B, up 8.6% from $56.33B the year before. Net income was $4.23B (a 6.9% net margin), or $2.36 per diluted share. Gross margin was 70.2% and operating margin was 24.6%. Operating activities generated $19.03B of cash, leaving $17.82B of free cash flow. At fiscal year end, AbbVie held $133.96B in total assets against $137.23B in total liabilities, including $5.23B of cash and equivalents.
Open the full interactive AbbVie financials → Quarterly statements, key ratios, valuation history and price charts.
AbbVie Key Stats
| Share Price | $274.36 |
|---|---|
| Market Cap | $485.89B |
| P/E Ratio | 116.3 |
| Dividend Yield | 2.47% |
| Revenue YoY Growth | +8.6% |
| 52-Week Range | $195.99 – $281.12 |
| Shares Outstanding | 1.77 billion (basic, 2026 Q2) |
AbbVie Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Cost of Goods Sold | $15.39B | $17.45B | $17.41B | $20.41B | $16.90B | $18.20B |
| Gross Profit | $30.42B | $38.75B | $40.64B | $33.90B | $39.43B | $42.96B |
| Operating Income | $11.36B | $17.92B | $18.12B | $12.76B | $9.14B | $15.07B |
| Pre-Tax Income | $3.40B | $12.99B | $13.48B | $6.25B | $3.72B | $6.60B |
| Income Tax | -$1.22B | $1.44B | $1.63B | $1.38B | -$570.0M | $2.36B |
| Net Income | $4.62B | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| Diluted EPS | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
AbbVie Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $15.78B | $16.62B | $15.00B | $16.99B |
| Net Income | $186.0M | $1.82B | $695.0M | $3.61B |
| Diluted EPS | $0.10 | $1.02 | $0.39 | $2.03 |
AbbVie Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.45B | $9.75B | $9.20B | $12.81B | $5.52B | $5.23B |
| Current Assets | $24.17B | $27.93B | $28.46B | $33.00B | $25.58B | $29.06B |
| Total Assets | $150.56B | $146.53B | $138.81B | $134.71B | $135.16B | $133.96B |
| Current Liabilities | $28.66B | $35.19B | $29.54B | $37.84B | $38.75B | $43.29B |
| Total Long-Term Debt | $86.02B | $76.67B | $63.27B | $59.38B | $67.14B | $65.00B |
| Total Liabilities | $137.49B | $131.12B | $121.55B | $124.35B | $131.84B | $137.23B |
| Shareholders' Equity | $13.08B | $15.41B | $17.25B | $10.36B | $3.33B | -$3.27B |
AbbVie Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $17.59B | $22.78B | $24.94B | $22.84B | $18.81B | $19.03B |
| Cash From Investing | -$37.56B | -$2.34B | -$623.0M | -$2.01B | -$20.82B | -$6.64B |
| Cash From Financing | -$11.50B | -$19.04B | -$24.80B | -$17.22B | -$5.21B | -$12.72B |
| Free Cash Flow | $16.79B | $21.99B | $24.25B | $22.06B | $17.83B | $17.82B |
| Dividends Paid | $7.72B | $9.26B | $10.04B | $10.54B | $11.03B | $11.66B |
Figures from AbbVie's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full AbbVie financials page for every line item.
AbbVie Company Profile
| Ticker | ABBV |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | North Chicago, Illinois |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001551152 |
Frequently Asked Questions
What was AbbVie's revenue in fiscal 2025?
AbbVie (ABBV) reported revenue of $61.16B for fiscal 2025.
What is AbbVie's annual revenue history?
AbbVie's annual revenue by fiscal year: 2020: $45.80B; 2021: $56.20B; 2022: $58.05B; 2023: $54.32B; 2024: $56.33B; 2025: $61.16B.
What was AbbVie's net income in fiscal 2025?
AbbVie reported net income of $4.23B for fiscal 2025.
What was AbbVie's earnings per share (EPS) in fiscal 2025?
AbbVie's diluted EPS was $2.36 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did AbbVie generate in fiscal 2025?
AbbVie generated $17.82B of free cash flow in fiscal 2025.
What was AbbVie's revenue last quarter?
In its most recent reported quarter (2026 Q2), AbbVie reported revenue of $16.99B.
How much debt does AbbVie have?
AbbVie reported $65.00B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of AbbVie are outstanding?
AbbVie reported a weighted average of 1.77 billion basic shares outstanding in 2026 Q2.
What is AbbVie's market cap?
Based on its latest closing price, AbbVie (ABBV) has a market capitalization of about $485.89B.
When does AbbVie's fiscal year end?
AbbVie's fiscal year end, as registered with the SEC, is December 31.
Where is AbbVie headquartered?
AbbVie lists its business address in North Chicago, Illinois in its SEC filings.